Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;48(7):2007-2012.
doi: 10.1161/STROKEAHA.117.017866. Epub 2017 Jun 16.

Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials

Joseph P Broderick  1 , Opeolu Adeoye  2 , Jordan Elm  2
Affiliations
Review

Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials

Joseph P Broderick et al. Stroke. 2017 Jul.
No abstract available

Keywords: clinical trial; modified Rankin Scale; multimedia; stroke.

PubMed Disclaimer

Conflict of interest statement

Conflicts-of-interests/Disclosure(s): Joseph Broderick: monies to Department of Neurology and Rehabilitation Medicine from Genentech for role on PRISMS Trial and from Astra-Zeneca as consultant for SOCRATES Trial.

Figures

Figure 1
Figure 1
Differences in means of the UW- mRS plotted against differences in proportions of mRS ≤ 3. Size of the circles is proportional to sample size of trial. Red circles are negative trials by both primary dichotomous measure and UW-mRS. Blue solid circles are positive by both measures. Blue circles with clear centers are positive by UW-mRS but negative by primary dichotomous endpoint (like IST3 with mRS of 0–1). Green circles with clear centers are positive by dichotomous primary endpoint but negative by UW-mRS (like PROACT II, TREVO II, and THRACE with mRS of 0–2 and ECASS III with mRS of 0–1). For the REVASCT trial, the two-sided p-value UW-mRS t-test is p=0.0502 which is larger than 0.05 and so it was coded as “- UW-mRS” (green circle*). The SAINT Trial analyzed the whole distribution of scores using the Cochran–Mantel–Haenszel test for its primary analysis that was just statistically positive (odds ratio, 1.20; 95 percent confidence interval, 1.01 to 1.42, green circle*). The ENCHANTED Trial was designed as a non-inferiority trial that was not non-inferior by primary endpoint.
See this image and copyright information in PMC

References

    1. Quinn TJ, Dawson J, Walters M. Dr John Rankin; his life, legacy and the 50th anniversary of the Rankin Stroke Scale. Scott Med J. 2008;53:44–47. - PubMed
    1. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–1054. - PMC - PubMed
    1. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–607. - PubMed
    1. Harrison JK, McArthur KS, Quinn TJ. Assessment scales in stroke: clinimetric and clinical considerations. Clin Interv Aging. 2013;8:201–211. - PMC - PubMed
    1. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin Scale: a systematic review. Stroke. 2009;40:3393–3395. - PubMed

Publication types